Business Wire

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials

7.9.2023 10:00:00 EEST | Business Wire | Press release

Share

Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/

CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.

Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.

CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.

Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.

CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.

Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.

Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”

About Cerba HealthCare

Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.

Cerba HealthCare, enlightening health.

Additional information is available at www.cerbahealthcare.com

About Cerba Research

We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.​

We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.​

Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.

For more information visit www.cerbaresearch.com

About CIRION

CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).

Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts:

Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com

CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231
desrocherss@cirion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vonage Named a Leader in the 2026 IDC MarketScape for Worldwide Communications Engagement Platforms29.4.2026 10:30:00 EEST | Press release

Vonage, a part of Ericsson (NASDAQ: ERIC), today announced that it has been positioned in the Leaders Category in the 2026 IDC MarketScape for the Worldwide Communications Engagement Platforms (CEP) sector. Vonage believes this recognition reflects Vonage's comprehensive communications platform that enables enterprises to reimagine customer and employee engagement at global scale. The IDC MarketScape: Worldwide Communications Engagement Platforms 2026 Vendor Assessment (Doc #US53542326, April 2026) provides a comprehensive assessment of select communications engagement platform (CEP) vendors, highlighting their strengths, challenges, and strategic direction to guide technology buyers in making informed decisions. Vonage believes its placement in the Leaders Category underscores the breadth and depth of its portfolio, underpinned by advanced AI capabilities. Built with enterprise businesses and developers in mind, Vonage provides the tools and flexibility to quickly build and customize

AI-driven Bot Attacks Surged 12.5x According to Thales Bad Bot Report29.4.2026 10:00:00 EEST | Press release

Thales today released the 2026 Bad Bot Report: Bad Bots in the Agentic Age, revealing a fundamental shift in how the internet operates, as AI-accelerated automation becomes a defining feature of modern digital infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428783532/en/ ©Thales The findings highlight three major structural changes: the emergence of AI agents as a new category of internet traffic, the dominance of automated activity over human interaction, and the rapid expansion of attacks targeting APIs and identity systems that serve as the backbone of digital business. AI Is Redefining Internet Traffic and Security The report shows that AI is not just increasing the volume of bot activity, but fundamentally changing its nature. In 2025, AI-driven bot attacks surged 12.5x compared to the previous year. More significantly, AI agents are now emerging as a third category of traffic, alongside traditional “g

OpenGate Capital Signs Definitive Agreement to Acquire Total Safety’s Europe and Middle East Division29.4.2026 10:00:00 EEST | Press release

OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire the European and the Middle Eastern (“EMEA”) division of Total Safety, a Littlejohn & Co. portfolio company. Total Safety EMEA is a leading provider of mission-critical safety and compliance solutions serving petrochemical and oil & gas customers across EMEA. The company focuses on workforce protection and regulatory compliance in complex, safety critical environments. Terms of the acquisition were not disclosed. Headquartered in Diepenbeek, Belgium, Total Safety EMEA offers a fully integrated, one-stop platform spanning safety services, rental equipment and product sales. Services include the deployment of highly trained personnel for critical safety operations, short- and long-term rental of essential equipment and the supply of personal protective equipment. As a trusted partner embedded in highly regulated environments, Total Safety EMEA supports clients

Hytera to Host Global Partner Summit 2026 in Shanghai, Advancing AI-Powered Mission-Critical Communications29.4.2026 09:00:00 EEST | Press release

Hytera Communications, a leading global provider of critical communications technologies and solutions, today announced it will host its highly anticipated Hytera Global Partner Summit (HGPS) 2026 in Shanghai on May 8, 2026, bringing together partners from more than 60 countries worldwide. Held under the theme "Advancing Together", this year’s summit marks the return of HGPS to China after several years overseas. As Hytera’s flagship event, it serves as a key platform to deepen collaboration, align strategic priorities, and unlock new opportunities for shared growth in an increasingly dynamic global market. The agenda will feature executive keynotes, new product launches, technology workshops, and partner-focused discussions, offering participants valuable insights into market trends and future development directions. A major highlight of HGPS 2026 will be the immersive exhibition pavilion, showcasing Hytera’s end-to-end portfolio and next-generation AI-powered solutions. Spanning sect

Autonomous University of Sinaloa (UAS) Releases Study on the Positive Economic Impacts of Pacifico Mexinol Project in Northern Sinaloa29.4.2026 01:39:00 EEST | Press release

As part of an ongoing joint effort between the academic and commercial sectors, stemming from a Collaboration Agreement between the Autonomous University of Sinaloa (UAS) and Pacifico Mexinol (a subsidiary of Transition Industries) signed in 2024, UAS released the findings of the economic effects study of the world's largest ultra-low-carbon methanol plant, located near Topolobampo, Ahome, Sinaloa. The Pacifico Mexinol project is aligned with the UN Sustainable Development Goals by promoting the use of clean energy, the utilization of treated wastewater, and climate change mitigation. It protects local ecosystems and will generate thousands of local jobs. The project represents more than the construction of industrial infrastructure; it is a trigger for economic growth for northern Sinaloa and Mexico. The study estimated the direct and indirect economic effects of the project’s investment in terms of employment, income, value added, and social well-being; identified regional developmen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye